-
1
-
-
80053339008
-
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
-
Ghany M.G., Nelson D.R., Strade D.B., Thomas D.L., Seeff L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1434.
-
(2011)
Hepatology
, vol.54
, pp. 1433-1434
-
-
Ghany, M.G.1
Nelson, D.R.2
Strade, D.B.3
Thomas, D.L.4
Seeff, L.B.5
-
2
-
-
0345188811
-
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line
-
Lohmann V., Korner F., Koch J., et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113.
-
(1999)
Science
, vol.285
, pp. 110-113
-
-
Lohmann, V.1
Korner, F.2
Koch, J.3
-
3
-
-
23044437222
-
Complete replication of hepatitis C virus in cell culture
-
Lindenbach B.D., Evans M.J., Syder A.J., et al. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
-
(2005)
Science
, vol.309
, pp. 623-626
-
-
Lindenbach, B.D.1
Evans, M.J.2
Syder, A.J.3
-
4
-
-
81855220325
-
The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors
-
Kwo P.Y., Vinayek R. The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors. Gut Liver 2011, 5:406-417.
-
(2011)
Gut Liver
, vol.5
, pp. 406-417
-
-
Kwo, P.Y.1
Vinayek, R.2
-
5
-
-
34247895578
-
The hepatitis C viral life cycle as a target for new antiviral therapies
-
Pawlotsky J.M., Chevaliez S., McHutchison J.G. The hepatitis C viral life cycle as a target for new antiviral therapies. Gastroenterology 2007, 132:1979-1998.
-
(2007)
Gastroenterology
, vol.132
, pp. 1979-1998
-
-
Pawlotsky, J.M.1
Chevaliez, S.2
McHutchison, J.G.3
-
6
-
-
0033920795
-
Replication of hepatitis C virus
-
Bartenschlager R., Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000, 81:1631-1648.
-
(2000)
J Gen Virol
, vol.81
, pp. 1631-1648
-
-
Bartenschlager, R.1
Lohmann, V.2
-
7
-
-
84876710927
-
-
Incivek (telaprevir) film coated tablets. Vertex. May. Available at [accessed April 12, 2012]
-
Incivek (telaprevir) film coated tablets. Vertex. May 2011. Available at [accessed April 12, 2012]. http://www.accessdata.fda.gov/drugsastda_docs/label/2011/201917lbl.pdf.
-
(2011)
-
-
-
8
-
-
84876744405
-
-
Victrelis (boceprevir) capsules. Merck. May. Available at: [accessed April 12, 2012].
-
Victrelis (boceprevir) capsules. Merck. May 2011. Available at: [accessed April 12, 2012]. http://www.accessdata.fda.gov/drugsastda_docs/label/2011/202258lbl.pdf.
-
(2011)
-
-
-
9
-
-
65449152185
-
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
-
McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838.
-
(2009)
N Engl J Med
, vol.360
, pp. 1827-1838
-
-
McHutchison, J.G.1
Everson, G.T.2
Gordon, S.C.3
-
10
-
-
65449171953
-
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
-
Hézode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-1850.
-
(2009)
N Engl J Med
, vol.360
, pp. 1839-1850
-
-
Hézode, C.1
Forestier, N.2
Dusheiko, G.3
-
11
-
-
77956268467
-
Efficacy of boceprevir and NS3 protease inhibitor in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized, multicentre phase 2 trial
-
Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir and NS3 protease inhibitor in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized, multicentre phase 2 trial. Lancet 2010, 376:705-716.
-
(2010)
Lancet
, vol.376
, pp. 705-716
-
-
Kwo, P.Y.1
Lawitz, E.J.2
McCone, J.3
-
12
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C infection
-
Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C infection. N Engl J Med 2011, 364:2405-2416.
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
-
13
-
-
79953173221
-
for SPRINT-2 investigators. Boceprevir for untreated chronic HCV genotype 1 infection.
-
Poordad F, McCone Jr. J, Bacon BR, et al.; for SPRINT-2 investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-206.
-
(2011)
N Engl J Med.
, vol.364
, pp. 1195-206
-
-
Poordad, F.1
McCone Jr., J.2
Bacon, B.R.3
-
14
-
-
84857368831
-
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients
-
Ramachandran P., Fraser A., Agarwal K., et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012, 35:647-662.
-
(2012)
Aliment Pharmacol Ther
, vol.35
, pp. 647-662
-
-
Ramachandran, P.1
Fraser, A.2
Agarwal, K.3
-
15
-
-
33644636312
-
Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease
-
Perni R.B., Almquist S.J., Byrn R.A., et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006, 50:899-909.
-
(2006)
Antimicrob Agents Chemother
, vol.50
, pp. 899-909
-
-
Perni, R.B.1
Almquist, S.J.2
Byrn, R.A.3
-
16
-
-
84856267331
-
Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C
-
Tungol A., Rademacher K., Schafer J.A. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C. J Manag Care Pharm 2011, 17:685-694.
-
(2011)
J Manag Care Pharm
, vol.17
, pp. 685-694
-
-
Tungol, A.1
Rademacher, K.2
Schafer, J.A.3
-
17
-
-
84876739567
-
-
U.S. Food and Drug Administration. Clinical pharmacology and biopharmaceutics review of telaprevir. Center for Drug Evaluation and Research. Available at: [accessed April 12, 2012].
-
U.S. Food and Drug Administration. Clinical pharmacology and biopharmaceutics review of telaprevir. Center for Drug Evaluation and Research. Available at: [accessed April 12, 2012]. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201917Orig1sClinPharmR.pdf.
-
-
-
-
18
-
-
84855244456
-
Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice
-
Hézode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver Int 2012, 32(Suppl. 1):32-38.
-
(2012)
Liver Int
, vol.32
, Issue.SUPPL. 1
, pp. 32-38
-
-
Hézode, C.1
-
19
-
-
80053319159
-
Anemia had no effect on efficacy outcomes in treatment-naïve patients who received telaprevir-based regimen in the Advance and Illuminate phase 3 studies
-
Sulkowski M.S., Reddy R., Afdhal N.H., et al. Anemia had no effect on efficacy outcomes in treatment-naïve patients who received telaprevir-based regimen in the Advance and Illuminate phase 3 studies. J Hepatol 2011, 54:S195.
-
(2011)
J Hepatol
, vol.54
-
-
Sulkowski, M.S.1
Reddy, R.2
Afdhal, N.H.3
-
20
-
-
27544439540
-
Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases
-
Lübbe J., Kerl K., Negro F., et al. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases. Br J Dermatol 2005, 153:1099.
-
(2005)
Br J Dermatol
, vol.153
, pp. 1099
-
-
Lübbe, J.1
Kerl, K.2
Negro, F.3
-
21
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
-
22
-
-
79959381354
-
Telaprevir for retreatment of HCV infection
-
Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
-
(2011)
N Engl J Med
, vol.364
, pp. 2417-2428
-
-
Zeuzem, S.1
Andreone, P.2
Pol, S.3
-
23
-
-
77950817619
-
Telaprevir for previously treated chronic hepatitis C infection
-
McHutchison J., Manns M.P., Muir A.J., et al. Telaprevir for previously treated chronic hepatitis C infection. N Engl J Med 2010, 362:1292-1303.
-
(2010)
N Engl J Med
, vol.362
, pp. 1292-1303
-
-
McHutchison, J.1
Manns, M.P.2
Muir, A.J.3
-
24
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
-
(2011)
N Engl J Med
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone, J.2
Bacon, B.R.3
-
25
-
-
79953176289
-
for HCV RESPOND-2 investigators. Boceprevir for previously treated chronic HCV genotype 1 infection.
-
Bacon BR, Gordon SC, Lawitz E, et al.; for HCV RESPOND-2 investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-206.
-
(2011)
N Engl J Med.
, vol.364
, pp. 1195-206
-
-
Bacon, B.R.1
Gordon, S.C.2
Lawitz, E.3
-
26
-
-
84876743861
-
-
FDA Antiviral Drugs Advisory Committee. Telaprevir briefing document April 28, 2011. Available from: [accessed April 12, 2012].
-
FDA Antiviral Drugs Advisory Committee. Telaprevir briefing document April 28, 2011. Available from: ; 2011 [accessed April 12, 2012]. http://www.fda.gov/downloads/Advisory-Committees/MeetingMaterials/Drugs/AntiviralDrugsAdvisory-Committee/UCM252562.pdf.
-
(2011)
-
-
-
27
-
-
84855924980
-
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals
-
Cacoub P., Mourliere M., Lübbe J., et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012, 56:455-463.
-
(2012)
J Hepatol
, vol.56
, pp. 455-463
-
-
Cacoub, P.1
Mourliere, M.2
Lübbe, J.3
-
28
-
-
74549143149
-
Severe cutaneous adverse reactions to drugs (SCAR): definitions, diagnostic criteria, genetic predisposition
-
Roujeau J.C., Allanore L., Liss Y., et al. Severe cutaneous adverse reactions to drugs (SCAR): definitions, diagnostic criteria, genetic predisposition. Dermatol Sin 2009, 27:203-209.
-
(2009)
Dermatol Sin
, vol.27
, pp. 203-209
-
-
Roujeau, J.C.1
Allanore, L.2
Liss, Y.3
-
29
-
-
84859955001
-
Review and management of drug interactions with boceprevir and telaprevir
-
Kiser J., Burton J., Anderson P., et al. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012, 55:1620-1628.
-
(2012)
Hepatology
, vol.55
, pp. 1620-1628
-
-
Kiser, J.1
Burton, J.2
Anderson, P.3
-
30
-
-
84876696241
-
Drug interactions
-
Lippincott Williams & Wilkins, Philadelphia, R.A. Helmes, D.J. Quan, E.T. Herfindal, D.R. Gourley (Eds.)
-
Middleton R.K. Drug interactions. Textbook of therapeutics: drug and disease management 2006, 47-72. Lippincott Williams & Wilkins, Philadelphia. 8th ed. R.A. Helmes, D.J. Quan, E.T. Herfindal, D.R. Gourley (Eds.).
-
(2006)
Textbook of therapeutics: drug and disease management
, pp. 47-72
-
-
Middleton, R.K.1
-
31
-
-
84856869185
-
A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients
-
Wilby J., Greanya E., Ford J., et al. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012, 11:179-185.
-
(2012)
Ann Hepatol
, vol.11
, pp. 179-185
-
-
Wilby, J.1
Greanya, E.2
Ford, J.3
-
32
-
-
80054908770
-
Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions
-
Seden K., Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS 2011, 6:514-526.
-
(2011)
Curr Opin HIV AIDS
, vol.6
, pp. 514-526
-
-
Seden, K.1
Back, D.2
-
33
-
-
77953501710
-
New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals
-
Seden K., Back D., Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. Antimicrob Chemother 2010, 65:1079-1085.
-
(2010)
Antimicrob Chemother
, vol.65
, pp. 1079-1085
-
-
Seden, K.1
Back, D.2
Khoo, S.3
-
34
-
-
84876701716
-
World Health Organization Drospirenone-containing combined oral contraceptives: possible increased risk of blood clots
-
Available in, [assessed in May 15, 2012]
-
World Health Organization Drospirenone-containing combined oral contraceptives: possible increased risk of blood clots. WHO Pharm Newslett 2011, 6:5. Available in, [assessed in May 15, 2012]. http://www.who.int/medicines/publications/PharmNewsletter6_11/en/index.html.
-
(2011)
WHO Pharm Newslett
, vol.6
, pp. 5
-
-
-
35
-
-
84855252404
-
Telaprevir user's guide
-
Liapakis A., Jacobson I. Telaprevir user's guide. Liver Int 2012, 32(Suppl. 1):17-26.
-
(2012)
Liver Int
, vol.32
, Issue.SUPPL. 1
, pp. 17-26
-
-
Liapakis, A.1
Jacobson, I.2
-
36
-
-
84876706581
-
-
Micromedex Healthcare Series. Portal capes. Available in: [assessed in March, 14]
-
Micromedex Healthcare Series. Portal capes. Available in: [assessed in March, 14, 2012]. http://www.thomsonhc.com.ez27.periodicos.capes.gov.br/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/ABFE31/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/DDC7A0/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/evidencexpert.IntermediateToDocumentLink%3FdocId=2865%26contentSetId=31%26title=BOCEPREVIR%26servicesTitle=BOCEPREVIR.
-
(2012)
-
-
-
37
-
-
80052585054
-
Cytochrome P450 drug interactions
-
[Full update October 2009]
-
Cytochrome P450 drug interactions. Pharmacist's Letter/Prescriber's Letter 2006, 22(2):220233. [Full update October 2009].
-
(2006)
Pharmacist's Letter/Prescriber's Letter
, vol.22
, Issue.2
, pp. 220233
-
-
|